0.05
0.00%
Close of 6 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MedMira
Its shares trade on TSX Venture under the ticker MIR.V. It has been listed since 1 December 1999. In the fiscal year to 31 July 2025, it reported revenue of C$240,509 and a net loss of C$4.5m. At that date it held total assets of C$3.7m and shareholders' equity of −C$22.6m.
MedMira, Inc. is a biotechnology company, which through its subsidiaries, engages in the research, development, manufacture, and commercialization of diagnostics and technology platforms. The company is headquartered in Halifax, Nova Scotia. The firm is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The firm operates through the rapid diagnostic products and services segment. The Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its research focuses on specific areas of the diagnostics market, such as rapid, point-of-care and in vitro sectors. The RVF technology platform includes a three component system: a test cartridge, multi-function buffer and InstantGold Cap. Its technology can be applied in healthcare, research and industrial markets. The company offers rapid tests for testing serum, plasma or whole blood specimens. The firm's tests are sold under brands, including Reveal, Multiplo and Miriad. The firm offers rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 1 Dec 1999
- Employees
- 65
- Website
- medmira.com ↗
Leadership
Pay as last reported
- Mr. Thomas BergmannIndependent Chairman of the Board
- Mr. Hermes ChanChief Executive Officer, DirectorC$100,000
- Mr. Markus MeileChief Financial Officer, since 2010C$60,000
- Mr. Steven CummingsIndependent Director, since 2007C$64,000
- Mr. Jianhe MaoIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- MedMira Inc possesses several strengths that contribute to its competitive advantage in the market. Firstly, the company has a strong intellectual property portfolio and innovative technological capabilities, allowing them to develop and produce cutting-edge medical diagnostic products.
- Secondly, MedMira Inc has established a reputable brand image and a loyal customer base. They have built strong relationships with healthcare professionals and organizations globally, which enhances their market presence and aids in the adoption of their products.
- Furthermore, the company benefits from a robust distribution network, enabling effective and efficient product reach across various geographic regions. This widespread network enhances their market coverage, customer accessibility, and potential for revenue growth.
- Lastly, MedMira Inc has a dedicated and experienced workforce consisting of skilled professionals who contribute to the company's success through their expertise, commitment, and passion for medical innovation.
Weaknesses
- Despite its strengths, MedMira Inc also faces certain weaknesses that may hinder its growth and competitive position. One significant weakness is the company's high dependence on a limited number of products for its revenue generation. This narrow product portfolio exposes MedMira to potential market fluctuations and increased vulnerability to competition.
- Additionally, the company's financial resources may limit its ability to invest in research and development activities, leading to potential delays in product innovation and technological advancements. This weakness may hinder MedMira's ability to keep up with rapidly evolving market trends and customer demands.
- Furthermore, MedMira Inc faces challenges related to regulatory compliance and obtaining necessary certifications in various jurisdictions. These compliance requirements can be time-consuming and costly, potentially affecting product launch timelines and market entry strategies.
Opportunities
- There are several opportunities that MedMira Inc can capitalize on to further strengthen its market position. Firstly, the growing demand for rapid and accurate medical diagnostics presents a significant opportunity for the company. By leveraging its innovative technologies and expanding product offerings, MedMira can tap into this increasing market demand and reach new customer segments.
- Additionally, global health crises, such as the recent COVID-19 pandemic, have highlighted the importance of diagnostic testing. MedMira Inc can leverage this heightened awareness to promote their products and establish strategic partnerships with healthcare authorities and organizations worldwide.
- Moreover, the continued advancements in telehealth and remote patient monitoring present an opportunity for MedMira Inc to develop and market diagnostic solutions that can be easily incorporated into these evolving healthcare delivery models.
Threats
- MedMira Inc operates in a highly competitive market, exposed to various threats that may impact its business. Increased competition from larger, well-established players with greater financial resources and market visibility could pose a threat to MedMira's market share and growth potential.
- Furthermore, regulatory changes or delays in obtaining necessary approvals can hinder MedMira's ability to launch new products and expand into different markets. Compliance with changing regulations and standards also requires ongoing investments in time and resources.
- Lastly, global economic uncertainty and potential disruptions in the healthcare and biotechnology industries may impact customer purchasing power, resulting in decreased demand for MedMira's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.